<DOC>
	<DOCNO>NCT02378974</DOCNO>
	<brief_summary>The objective study evaluate safety potential therapeutic effect per dose Cordstem-ST Intravenous Transplantation Cerebral Infarction subject comprise 2 treatment cohort : Cohort 1 : Cordstem-ST 2.0 x 10^8 cell Placebo day 0 Cohort 2 : Cordstem-ST 2.0 x 10^8 cell Placebo day 0 day 7</brief_summary>
	<brief_title>Evaluation Safety Potential Therapeutic Effects After Intravenous Transplantation Cordstem-ST Patients With Cerebral Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female subject 19 80 year age ( inclusive ) time screen visit 2 . Subjects able receive intravenous CordstemST Transplantation within 7 day ( 168 hour ) stroke onset 3 . Subjects diagnosis Cerebral Infarction confirm follow criterion assess screen visit NIHSS score 5 20 ( inclusive ) Acute ischemic lesion involve anterior circulation territory identify diffusion weight MRI 4 . Signed informed consent Exclusion Criteria 1 . History intracranial hemorrhage 2 . Subjects suspect undergo thrombolytic therapy , endarterectomy cerebral artery stenting study period . Subjects receive former procedure due cerebral infarction 3 month ago , eligible . 3 . Subjects hemorrhagic transformation brain image , except petechial hemorrhage ( 'H1 ' accord ECASS classification ) 4 . Subjects high risk develop brain herniation 5 . History dementia 6 . History epilepsy 7 . Subjects treat diagnosed schizophrenia , depression , bipolar disorder within past 6 month 8 . Subjects recent ( â‰¤3 month ) myocardial infarction stroke index stroke . 9 . Subjects must follow condition laboratory test ALT AST : More 2.5 time upper limit normal Serum creatinine : More 1.5 time upper limit normal Total bilirubin : More 2.5 time upper limit normal Platelet count : le low limit narmal 10 . Subjects HBV , HCV , HIV , VDRL positive 11 . Subjects poor general condition due medical condition subject severe cardiovascular , gastrointestinal , pulmonary , endocrinologic diseases 12 . Subjects active lung disease , base chest Xray 13 . Subjects abnormal coagulopathic condition ( thrombocytopenia , congenital coagulopathy , etc. ) . Medical use oral anticoagulant permit . 14 . Subjects know allergy protein product ( Bovine serum ) use cell production process . 15 . Subjects history pulmonary embolism deep vein thrombosis 16 . Subjects history malignancy 17 . Pregnant lactate woman 18 . Women childbearing age reject practice contraception one follow method Use condom Use contraceptive ( oral , dermal , injectable ) Use intrauterine contraceptive device 19 . Subjects history alcohol abuse ( &gt; 30g/day ) drug abuse 20 . Subjects undergo MRI scan 21 . Subjects conduct schedule monitoring visit 22 . Subjects determine inappropriate investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cerebral Infarction</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Stroke</keyword>
</DOC>